We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer.
- Authors
Lloyd, Richard E.; Jones, Stephen E.; Salmon, Sydney E.; Lloyd, R E; Jones, S E; Salmon, S E
- Abstract
We treated 56 women with advanced metastatic breast cancer who had not received prior chemotherapy in a comparative trial of cytotoxic chemotherapy with low-dose adriamycin plus cyclophosphamide alone or in combination with the androgenic steroid calusterone. The response rate to chemohormonal therapy (65%) could not be shown to be statistically better than that for chemotherapy alone (53%) for this size patient population. However, the median remission duration (21.5 months) was significantly prolonged over the 11.5-month remission duration for chemotherapy alone (p = 0.03). The median survival of the chemohormonal therapy group was 23.5 months, whereas that for chemotherapy alone was 13.5 months (p = 0.05). These results indicate that the addition of a potent hormonal agent to effective cytotoxic chemotherapy improves the results of treatment of women with metastatic breast cancer.
- Subjects
BREAST tumors; COMBINATION drug therapy; CLINICAL trials; COMPARATIVE studies; DOXORUBICIN; RESEARCH methodology; MEDICAL cooperation; METASTASIS; RESEARCH; TESTOSTERONE; TIME; EVALUATION research; DISEASE remission; CYCLOPHOSPHAMIDE
- Publication
Cancer (0008543X), 1979, Vol 43, Issue 1, p60
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(197901)43:1<60::AID-CNCR2820430108>3.0.CO;2-M